Rest-Of-Europe Preimplantation Genetic Testing Market Size, Share,Trends, Growth Analysis Report, 2030

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of Europe Preimplantation Genetic Testing Market analysis

Part of: Preimplantation Genetic Testing Market (Global)

The Rest Of Europe Preimplantation Genetic Testing Market was valued at $33.6 Million in 2025 and projected to reach to $56.7 Million by 2030, representing a compound annual growth rate of 11.0%. Rest Of Europe's Preimplantation Genetic Testing market demonstrates strong momentum with an 11% CAGR, significantly outperforming global benchmarks.

Rest Of Europe Preimplantation Genetic Testing Market (2025-2030) : Size and Share

CAGR of

USD Million

Rest Of Europe Preimplantation Genetic Testing Market Trends and Insights

Rest Of Europe's market growth is driven by increasing adoption of assisted reproductive technologies, rising awareness of genetic screening benefits, and supportive regulatory frameworks across multiple countries.
The region's 11.0% compound annual growth rate outpaces the global average, reflecting strong demand for PGT services among fertility clinics and patients seeking to reduce genetic disease transmission. Rest Of Europe's market dynamics are shaped by improving healthcare infrastructure, growing investment in reproductive medicine, and expanding insurance coverage for genetic testing procedures.
Rest Of Europe demonstrates significant potential as fertility treatment accessibility increases and genetic screening becomes standard practice in IVF protocols.
The forecast period through 2030 indicates sustained momentum, with Rest Of Europe positioned as a key growth market within the broader European PGT landscape..

Key Market Statistics

CAGR (2025-2030) 11.0% CAGR
Market Size, 2025 ~USD 33.6 Million
Forecast, 2030 ~USD 56.7 Million
Country Rest Of Europe

Rest Of Europe Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

Rest Of Europe's Preimplantation Genetic Testing market is valued at USD 33.6 million in 2025, with a projected CAGR of 11% through 2030, outpacing the global growth rate of 10.5%.

Regulatory Support :

Multiple European countries maintain supportive regulatory frameworks for genetic screening and assisted reproductive technologies, facilitating market expansion and clinical adoption across the region.

Rising ART Adoption :

Increasing adoption of assisted reproductive technologies across Rest Of Europe is driving demand for preimplantation genetic testing as a standard screening procedure in fertility clinics.

Awareness & Education :

Growing patient and healthcare provider awareness of genetic screening benefits is accelerating market penetration and acceptance of PGT services throughout Rest Of European markets.

Rest Of Europe Preimplantation Genetic Testing Market Dynamics

The region benefits from established healthcare infrastructure, progressive regulatory environments, and increasing fertility treatment demand across multiple countries.
Healthcare providers are integrating PGT into standard ART protocols, supported by rising patient awareness and improved accessibility to genetic screening services. Looking ahead to 2030, the market is expected to reach USD 56.7 million, driven by technological advancements, declining testing costs, and expanding clinical applications.
Continued investment in reproductive medicine infrastructure and growing emphasis on genetic health screening will sustain robust growth.
Rest Of Europe's diverse market landscape presents opportunities for both established players and innovative entrants targeting specific country-level healthcare systems..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies

Polymerase Chain Reaction (PCR)
Reagents
Assay Kits
Bioinformatics
Flow Cytometry

Top Companies

Thermo Fisher Scientific Inc.
Illumina, Inc.
Agilent Technologies, Inc.
Qiagen N.V.
Danaher Corporation

Biotechnology

Top Technologies

Reagents
Polymerase Chain Reaction (PCR)
Stem Cells
Assay Kits
Flow Cytometers

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.

Key Takeaways

Rest Of Europe's PGT market is valued at USD 33.6 million in 2025 and will grow to USD 56.7 million by 2030, representing a 68.6% increase over the forecast period.
Rest Of Europe's 11.0% CAGR exceeds the global average of 10.5%, indicating accelerated regional adoption of preimplantation genetic testing technologies.
Rest Of Europe benefits from expanding fertility clinic networks, improved reimbursement policies, and heightened patient awareness driving market penetration.
Rest Of Europe's growth trajectory reflects increasing demand for genetic disease screening and chromosomal abnormality detection in assisted reproduction cycles.

Preimplantation Genetic Testing Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	SINGLE GENE DISORDERS (Application)
Forecast Period	2025�2030
Growth Rate	CAGR of 10.5% from 2025 to 2030
Largest Segment	PREIMPLANTATION GENETIC SCREENING (Procedure Type)
Market Size Base Year (Billions)	~USD 0.69 (2025)
Revenue Forecast (Billions)	~USD 1.14 (2030)
Segments Covered	Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

Rest Of Europe Preimplantation Genetic Testing Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product & Service

Instruments
Reagents & Consumables
Software & Services

By Procedure Type

Preimplantation Genetic Diagnosis
Preimplantation Genetic Screening

By Technology

Comparative Genomic Hybridization
Fluorescence In Situ Hybridization
Next-Generation Sequencing
Polymerase Chain Reaction
Single-Nucleotide Polymorphism

By Application

Aneuploidy
Gender Identification
Hla Typing
Single Gene Disorders
Structural Chromosomal Abnormalities
X-Linked Disorders

By Type

Deletions
Duplications
Inversions
Translocations

By Type Of Cycle

Fresh Donor
Fresh Non-Donor
Frozen Donor
Frozen Non-Donor

By End User

Diagnostic Laboratories
Fertility Clinics
Hospitals
Other End Users

Target Audience

Fertility Clinic Operators : Clinic managers and medical directors need Rest Of Europe market data to evaluate PGT service expansion opportunities, understand regional demand trends, and optimize service offerings across multiple countries.
Diagnostic Laboratory Providers : Genetic testing companies require regional market insights to identify growth opportunities, assess competitive landscapes, and develop targeted expansion strategies within Rest Of Europe's diverse healthcare systems.
Medical Device & IVF Equipment Manufacturers : Equipment suppliers need Rest Of Europe market intelligence to understand adoption rates, regulatory requirements, and customer demand for integrated PGT solutions in regional fertility centers.
Healthcare Investors & Consultants : Investment firms and management consultants require detailed Rest Of Europe market data to evaluate portfolio opportunities, assess growth potential, and support due diligence in reproductive medicine sectors.
Healthcare Policy & Regulatory Bodies : Government agencies and regulatory organizations need market insights to inform policy development, understand clinical adoption trends, and ensure appropriate oversight of genetic testing services across Rest Of Europe.

Key Companies in the Rest Of Europe Preimplantation Genetic Testing Market

Company	HQ	Ownership	Strongest segments
CIMARON LABEL			Pressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
THERMO FISHER SCIENTIFIC INC.	United States	Public Company	Laboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
AGILENT TECHNOLOGIES, INC.	United States	Public Company	Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
REVVITY	United States	Public Company	Reagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
COOPERCOMPANIES	United States	Public Company	Spherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
ABBOTT	United States	Public Company	Diagnostic Products,Medical Devices,Nutritional Products,
TAKARA BIO INC.	Japan	Private Company	Research reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
VITROLIFE	Sweden	Public Company	IVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

CIMARON LABEL

Insufficient information provided to generate description.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

REVVITY

Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

COOPERCOMPANIES

CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

ABBOTT

Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

TAKARA BIO INC.

Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

VITROLIFE

Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

Reasons to Buy this Report

Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Europe, including 2025 baseline (USD 33.6M) and 2030 forecasts (USD 56.7M), enabling accurate regional business planning and investment decisions.
Growth Trajectory Analysis : Understand Rest Of Europe's 11% CAGR performance relative to global 10.5% growth, identifying the region as a high-growth opportunity with above-average expansion potential through 2030.
Regulatory & Market Drivers : Gain insights into supportive regulatory frameworks and country-specific adoption factors driving PGT market growth across Rest Of Europe, informing market entry and expansion strategies.
Competitive Positioning : Benchmark your organization against regional market dynamics and identify growth opportunities in Rest Of Europe's expanding ART and genetic screening sectors for strategic positioning.
Investment & Expansion Planning : Leverage detailed Rest Of Europe market intelligence to support investment decisions, partnership development, and resource allocation for fertility clinics and diagnostic service providers.

Frequently asked questions

What is the current market size of PGT in Rest Of Europe?

Rest Of Europe's Preimplantation Genetic Testing market is valued at USD 33.6 million in 2025.

What is the projected market size for Rest Of Europe by 2030?

Rest Of Europe's PGT market is forecast to reach USD 56.7 million by 2030.

What is the CAGR for Rest Of Europe's PGT market?

Rest Of Europe's Preimplantation Genetic Testing market is growing at a compound annual growth rate of 11.0% from 2025 to 2030.

How does Rest Of Europe's growth compare to global trends?

Rest Of Europe's 11.0% CAGR exceeds the global average of 10.5%, demonstrating faster regional market expansion.

What factors are driving growth in Rest Of Europe's PGT market?

Rest Of Europe's market growth is driven by increased ART adoption, rising genetic screening awareness, supportive regulations, expanding fertility clinic infrastructure, and improving insurance coverage.

RESEARCH METHODOLOGY

This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

Secondary Research

Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

Data Triangulation

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

Market Definition

Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

Preimplantation genetic screening for abnormal chromosome number (PGT-A)
Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

Stakeholders

Contract research organizations (CROs)
Contract development and manufacturing organizations (CDMOs)
In vitro fertilization (IVF) centers and fertility clinics
Life science companies
Fertility clinics
Academic & research institutes
Private research institutes
Venture capitalists & investors
Market research & consulting firms
Government associations
Medical institutions & universities
Hospitals & clinics

Report Objectives

To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

Get the Full Preimplantation Genetic Testing Market Report

Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)